我们是否已经准备好进行报销了？真实世界证据在卫生技术评估方面的发展综述：第 14 部分。
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14.
机构信息
Lane Clark & Peacock LLP, London, W1U 1DQ, UK.
Department of Population Health Sciences, King's College London, London, SE1 9NH, UK.
出版信息
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.
Abstract
In this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.
摘要
在本次最新更新中，我们重点介绍了以下内容：美国 FDA 发布的关于真实世界数据（RWD）和真实世界证据（RWE）定义的出版物；学术研究人员发布的关于目标试验模拟演示项目的出版物；英国国家卫生与保健优化研究所（NICE）发布的关于其 RWE 框架发布一周年的出版物；以及 NICE 和 Flatiron Health 发布的关于美国 RWD 在英国初始卫生技术评估决策中的效用的出版物。
相似文献
1
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14.
J Comp Eff Res. 2024 Jan;13(1):e230189. doi: 10.57264/cer-2023-0189. Epub 2024 Jan 4.
2
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.
J Comp Eff Res. 2022 May;11(7):473-475. doi: 10.2217/cer-2022-0043. Epub 2022 Mar 9.
3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 8.
J Comp Eff Res. 2022 Sep;11(13):915-917. doi: 10.2217/cer-2022-0103. Epub 2022 Jun 15.
4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 7.
J Comp Eff Res. 2022 Jul;11(10):699-701. doi: 10.2217/cer-2022-0071. Epub 2022 May 4.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13.
J Comp Eff Res. 2023 Nov;12(11):e230141. doi: 10.57264/cer-2023-0141. Epub 2023 Sep 15.
6
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16.
J Comp Eff Res. 2024 Aug;13(8):e240095. doi: 10.57264/cer-2024-0095. Epub 2024 Jul 5.
7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.
J Comp Eff Res. 2024 May;13(5):e240033. doi: 10.57264/cer-2024-0033. Epub 2024 Mar 28.
8
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
J Comp Eff Res. 2024 Sep;13(9):e240061. doi: 10.57264/cer-2024-0061. Epub 2024 Aug 12.
9
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11.
J Comp Eff Res. 2023 May;12(5):e230008. doi: 10.57264/cer-2023-0008. Epub 2023 Apr 13.
10
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10.
J Comp Eff Res. 2023 Jan;12(1):e220194. doi: 10.2217/cer-2022-0194. Epub 2022 Dec 1.
引用本文的文献
1
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.
J Comp Eff Res. 2025 Jul;14(7):e250063. doi: 10.57264/cer-2025-0063. Epub 2025 May 12.
2
Effectiveness of chemotherapy with/without radiotherapy for stage IVb esophageal squamous cell carcinoma: a population-based target trial emulation study.
Discov Oncol. 2025 May 6;16(1):672. doi: 10.1007/s12672-025-02451-0.
3
Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study.
Thorac Cancer. 2024 Aug;15(24):1779-1791. doi: 10.1111/1759-7714.15404. Epub 2024 Jul 16.
4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.
J Comp Eff Res. 2024 May;13(5):e240033. doi: 10.57264/cer-2024-0033. Epub 2024 Mar 28.
本文引用的文献
1
Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Clin Transl Sci. 2024 Jan;17(1):e13702. doi: 10.1111/cts.13702.
2
The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework.
J Comp Eff Res. 2023 Nov;12(11):e230135. doi: 10.57264/cer-2023-0135. Epub 2023 Oct 19.
3
When can real-world data generate real-world evidence?
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5715. doi: 10.1002/pds.5715. Epub 2023 Oct 19.
4
Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study.
BMJ Open. 2023 Oct 17;13(10):e074559. doi: 10.1136/bmjopen-2023-074559.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12.
J Comp Eff Res. 2023 Jul;12(7):e230092. doi: 10.57264/cer-2023-0092. Epub 2023 Jun 22.
6
Emulating Target Trials With Real-World Data to Inform Health Technology Assessment: Findings and Lessons From an Application to Emergency Surgery.
Value Health. 2023 Aug;26(8):1164-1174. doi: 10.1016/j.jval.2023.04.010. Epub 2023 May 8.
7
Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?
BMJ. 2023 Mar 2;380:e073100. doi: 10.1136/bmj-2022-073100.
8
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.
BMJ Evid Based Med. 2024 Jan 19;29(1):1-5. doi: 10.1136/bmjebm-2022-112091.
9
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.
NPJ Precis Oncol. 2022 Oct 25;6(1):76. doi: 10.1038/s41698-022-00316-1.
10
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.
Pharmacoepidemiol Drug Saf. 2023 Jan;32(1):44-55. doi: 10.1002/pds.5507. Epub 2022 Oct 10.
Zotero 插件